- Home
- EVAX vs BIAF Comparison
EVAX vs BIAF Comparison
Compare EVAX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- BIAF
- Stock Information
- Founded
- EVAX 2008
- BIAF 2014
- Country
- EVAX Denmark
- BIAF United States
- Employees
- EVAX N/A
- BIAF N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EVAX Health Care
- BIAF Health Care
- Exchange
- EVAX Nasdaq
- BIAF Nasdaq
- Market Cap
- EVAX 10.8M
- BIAF 12.2M
- IPO Year
- EVAX 2021
- BIAF 2022
- Fundamental
- Price
- EVAX $3.13
- BIAF $0.28
- Analyst Decision
- EVAX Strong Buy
- BIAF Hold
- Analyst Count
- EVAX 2
- BIAF 1
- Target Price
- EVAX $10.00
- BIAF N/A
- AVG Volume (30 Days)
- EVAX 134.8K
- BIAF 9.1M
- Earning Date
- EVAX 05-27-2025
- BIAF 05-15-2025
- Dividend Yield
- EVAX N/A
- BIAF N/A
- EPS Growth
- EVAX N/A
- BIAF N/A
- EPS
- EVAX N/A
- BIAF N/A
- Revenue
- EVAX $3,293,000.00
- BIAF $8,809,228.00
- Revenue This Year
- EVAX N/A
- BIAF N/A
- Revenue Next Year
- EVAX N/A
- BIAF $20.00
- P/E Ratio
- EVAX N/A
- BIAF N/A
- Revenue Growth
- EVAX 2555.64
- BIAF 78.40
- 52 Week Low
- EVAX $1.20
- BIAF $0.16
- 52 Week High
- EVAX $19.95
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- EVAX 75.25
- BIAF 46.46
- Support Level
- EVAX $2.58
- BIAF $0.24
- Resistance Level
- EVAX $2.84
- BIAF $0.32
- Average True Range (ATR)
- EVAX 0.25
- BIAF 0.06
- MACD
- EVAX 0.10
- BIAF 0.01
- Stochastic Oscillator
- EVAX 96.79
- BIAF 28.07
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.